Gossamer Bio GOSS 深 滬
等待開盤 08-08 09:30:00 美东时间
1.74
-0.240
-12.12%
華盛通- 最 高2.02
- 今 開2.00
- 成交量 374.59万股
- 最 低 1.715
- 昨 收 1.98
- 總市值 3.95亿
- 52周最高 2.23
- 市盈率 靜 --
- 換手率 1.65%
- 52周最低 0.6617
- 委 比 98.84%
- 總股本 2.27亿
- 歷史最高 27.15
- 量 比 1.01
- 振 幅 15.40%
- 歷史最低 0.4525
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
Gossamer shares are trading lower. The company reported Q2 financial results.
Gossamer shares are trading lower. The company reported Q2 financial results.
08-07 00:57
Wedbush Maintains Outperform on Gossamer Bio, Raises Price Target to $5
Wedbush analyst Laura Chico maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and raises the price target from $4 to $5.
08-06 23:59
Gossamer Bio Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $11.49M Beat $4.34M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.03 percent. This is a 177.27 percent decrease over earnings of $0.22 per share from the
08-06 04:24
期权扫描丨SoFi绩后大涨，遭多笔看跌期权押注；联合健康绩后期权成交量暴增
SoFi绩后大涨，遭多笔看跌期权押注；联合健康绩后跌超7%，期权成交量暴增；AMD隔夜涨2.18%，多笔看跌期权大单成交超5万张>>
07-30 19:38
Scotiabank Initiates Coverage On Gossamer Bio with Sector Outperform Rating, Announces Price Target of $11
Scotiabank analyst Greg Harrison initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Sector Outperform rating and announces Price Target of $11.
07-14 19:53
Gossamer Bio Approves 2019 Incentive Award Plan
Gossamer Bio ( ($GOSS) ) has provided an announcement. On June 25, 2025, Gossam...
06-26 04:42
Gossamer Bio shares are trading higher after the company completed enrollment in its registrational Phase 3 PROSERA study for pulmonary arterial hypertension
Gossamer Bio shares are trading higher after the company completed enrollment i...
06-16 19:36
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
Gossamer Bio Q1 EPS $(0.16) Beats $(0.18) Estimate, Sales $9.89M Beat $4.07M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the
05-16 04:03
